NCTId,BriefTitle,Phase,SponsorName,success_rate,median_approval_year,mean_approval_year,pct10_approval_year,pct90_approval_year,earliest_approval_year,latest_approval_year,japan_median_approval_year,japan_mean_approval_year,japan_pct10_approval_year,japan_pct90_approval_year,japan_earliest_approval_year,japan_latest_approval_year,japan_median_delay_years
NCT04945772,Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE],PHASE2,Nanoscope Therapeutics Inc.,1.0,2026.0,2025.9988,2026.0,2026.0,2025,2026,2031.0,2030.6412,2030.0,2032.0,2029,2033,4.991281857133492
NCT06388200,A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa,PHASE3,Ocugen,1.0,2027.0,2027.0,2027.0,2027.0,2027,2027,2032.0,2032.2414,2031.0,2033.0,2030,2034,4.993756733929585
NCT05203939,Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis,"PHASE1, PHASE2",Ocugen,1.0,2027.0,2027.0,2027.0,2027.0,2027,2027,2032.0,2032.2398,2031.0,2033.0,2030,2034,5.000543116478321
NCT06275620,A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN),PHASE2,Beacon Therapeutics,1.0,2029.0,2028.9966,2029.0,2029.0,2028,2030,2034.0,2033.9946,2033.0,2035.0,2031,2036,5.009497530194265
NCT04850118,A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP,"PHASE2, PHASE3",Beacon Therapeutics,1.0,2029.0,2028.9957,2029.0,2029.0,2028,2030,2034.0,2033.9862,2033.0,2035.0,2031,2036,5.001217538944167
NCT00999609,Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis,PHASE3,"Spark Therapeutics, Inc.",0.719,2029.0,2029.148678720445,2028.0,2030.0,2027,2031,2034.0,2034.1465924895688,2033.0,2035.0,2031,2037,4.996541379858244
NCT06333249,A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE),PHASE2,Beacon Therapeutics,1.0,2029.0,2028.991,2029.0,2029.0,2028,2030,2034.0,2033.9843,2033.0,2035.0,2031,2036,5.000714298948223
NCT06455826,MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby),PHASE1,PYC Therapeutics,1.0,2030.0,2029.8323,2029.0,2030.0,2029,2031,2035.0,2034.7557,2034.0,2036.0,2032,2037,5.007004614507277
NCT06852963,A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001,"PHASE1, PHASE2",PYC Therapeutics,1.0,2030.0,2029.8287,2029.0,2030.0,2029,2031,2035.0,2034.7645,2034.0,2036.0,2032,2037,5.0239225014293645
NCT03584165,Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa,PHASE3,"NightstaRx Ltd, a Biogen Company",0.7088,2032.0,2032.117099322799,2031.0,2033.0,2030,2034,2037.0,2037.1139954853272,2036.0,2039.0,2033,2040,4.999283461961259
NCT05537220,Oral N-acetylcysteine for Retinitis Pigmentosa,PHASE3,Johns Hopkins University,0.7167,2032.0,2032.0958560066974,2031.0,2033.0,2030,2034,2037.0,2037.1105064880703,2036.0,2039.0,2034,2041,5.01100908410167
NCT04356716,Sildenafil for Treatment of Choroidal Ischemia,PHASE2,Columbia University,0.5543,2036.0,2036.608695652174,2034.0,2040.0,2032,2044,2041.0,2041.619159300018,2039.0,2045.0,2036,2049,5.008895461365381
NCT06628947,A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa,PHASE2,"Kiora Pharmaceuticals, Inc.",0.5618,2036.0,2036.3196867212532,2034.0,2039.0,2031,2043,2041.0,2041.3428266286935,2039.0,2044.0,2035,2049,5.0072261124566335
NCT06627179,Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene,PHASE2,Laboratoires Thea,0.4982,2036.0,2036.6493376154156,2034.0,2040.0,2032,2044,2041.0,2041.6429144921717,2039.0,2045.0,2036,2049,4.99425480535438
NCT02065011,"A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B",PHASE2,Sanofi,0.5627,2036.0,2036.6015638883953,2034.0,2040.0,2032,2043,2041.0,2041.5901901546117,2039.0,2045.0,2035,2049,5.003849607381859
NCT05909488,Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II,"PHASE2, PHASE3",PT. Prodia Stem Cell Indonesia,0.5543,2036.0,2036.661915930002,2034.0,2040.0,2032,2043,2041.0,2041.6620963377231,2039.0,2045.0,2036,2049,5.004761359046917
NCT06912633,"Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)",PHASE2,"jCyte, Inc",0.5631,2036.0,2036.5595808914936,2034.0,2040.0,2032,2043,2041.0,2041.5601136565442,2039.0,2045.0,2036,2049,5.01064524815744
NCT04794101,Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene,PHASE3,"Janssen Research & Development, LLC",0.2001,2036.0,2036.4047976011993,2035.0,2037.0,2034,2039,2041.0,2041.424787606197,2040.0,2043.0,2038,2045,5.042418682005148
NCT05926583,A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa,PHASE3,Janssen Pharmaceutical K.K.,0.1947,2036.0,2036.432460195172,2035.0,2038.0,2034,2039,2041.0,2041.4232152028762,2040.0,2043.0,2038,2045,4.985713009454513
NCT06646289,A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP),PHASE2,"Janssen Research & Development, LLC",0.5097,2036.0,2036.6099666470473,2034.0,2040.0,2032,2043,2041.0,2041.615263880714,2039.0,2045.0,2036,2049,5.0081378744041665
NCT01736059,Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy,PHASE1,"University of California, Davis",0.4807,2037.0,2037.157270646973,2035.0,2040.0,2032,2044,2042.0,2042.1726648637405,2039.0,2045.0,2036,2050,5.004114787757589
NCT02464436,Safety and Tolerability of hRPC in Retinitis Pigmentosa,"PHASE1, PHASE2",ReNeuron Limited,0.4825,2037.0,2037.1334715025907,2035.0,2040.0,2032,2044,2042.0,2042.1382383419689,2039.0,2045.0,2036,2050,4.988143060675289
NCT06319872,The Effects of Disulfiram (AntabuseÂ®) on Visual Acuity in Patients With Retinal Degeneration,PHASE1,University of Rochester,0.4341,2040.0,2040.470859249021,2037.0,2044.0,2034,2050,2045.0,2045.4593411656301,2042.0,2049.0,2038,2056,4.978760637715585
NCT03316560,Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations,"PHASE1, PHASE2",Beacon Therapeutics,0.4379,2040.0,2040.5323133135419,2037.0,2044.0,2033,2050,2045.0,2045.5151861155514,2042.0,2049.0,2038,2055,4.995559790933033
NCT06787482,"Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","PHASE1, PHASE2",Ace Cells Lab Limited,0.4812,2040.0,2040.4576059850374,2037.0,2044.0,2034,2050,2045.0,2045.4781795511221,2042.0,2049.0,2038,2055,5.018878485730565
NCT06952842,Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation,"PHASE1, PHASE2","Chigenovo Co., Ltd",0.4446,2040.0,2040.411381016644,2037.0,2044.0,2034,2050,2045.0,2045.4289248762932,2042.0,2049.0,2038,2056,5.009467228136481
NCT03328130,Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene,"PHASE1, PHASE2",eyeDNA Therapeutics,0.4434,2040.0,2040.4754172304918,2037.0,2044.0,2034,2050,2045.0,2045.4589535408209,2042.0,2049.0,2038,2056,4.9964617800368
NCT05748873,Promising ROd-cone DYstrophy Gene TherapY,"PHASE1, PHASE2",SparingVision,0.4326,2040.0,2040.380027739251,2037.0,2044.0,2033,2051,2045.0,2045.3804900601017,2042.0,2049.0,2038,2056,4.995132845784831
NCT06291935,Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene,PHASE1,VeonGen Therapeutics GmbH,0.4313,2040.0,2040.4808717829817,2037.0,2044.0,2033,2049,2045.0,2045.5047530721076,2042.0,2049.0,2038,2054,5.029118368413956
NCT04123626,A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene,"PHASE1, PHASE2",ProQR Therapeutics,0.4376,2040.0,2040.4149908592321,2037.0,2044.0,2034,2049,2045.0,2045.4444698354662,2042.0,2049.0,2038,2055,5.0285529515570335
NCT03374657,"A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa","PHASE1, PHASE2",Novartis Pharmaceuticals,0.4779,2040.0,2040.3739275999162,2037.0,2044.0,2033,2049,2045.0,2045.4038501778614,2042.0,2049.0,2038,2055,5.004257244600172
NCT06292650,Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients,EARLY_PHASE1,Zhongmou Therapeutics,0.4436,2040.0,2040.4050946798918,2037.0,2044.0,2034,2050,2045.0,2045.405996393147,2042.0,2049.0,2038,2056,5.004321807992094
NCT03326336,Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa,"PHASE1, PHASE2",GenSight Biologics,0.47,2040.0,2040.4344680851063,2037.0,2044.0,2034,2051,2045.0,2045.45,2042.0,2049.0,2037,2056,5.0136603358710685
NCT03999021,FIGHT-RP 1 Extension Study,PHASE1,Johns Hopkins University,0.4853,2040.0,2040.3756439315887,2037.0,2044.0,2033,2049,2045.0,2045.3842983721408,2042.0,2049.0,2037,2055,5.000390942115004
NCT04284293,CNS10-NPC for the Treatment of RP,PHASE1,Cedars-Sinai Medical Center,0.4778,2040.0,2040.4012138970281,2037.0,2044.0,2034,2049,2045.0,2045.4093763080787,2042.0,2049.0,2038,2056,5.011425789247534
NCT06242379,Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Mahidol University,0.4911,2040.0,2040.4259824882915,2037.0,2044.0,2033,2049,2045.0,2045.4424760741192,2042.0,2049.0,2037,2055,5.024322351363154
NCT06492850,Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa,"PHASE1, PHASE2",Frontera Therapeutics,0.4366,2040.0,2040.473202015575,2037.0,2044.0,2034,2049,2045.0,2045.479157123225,2042.0,2049.0,2038,2055,5.016605794026274
NCT05874310,Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa,EARLY_PHASE1,Frontera Therapeutics,0.4429,2040.0,2040.369835177241,2037.0,2044.0,2033,2050,2045.0,2045.3714156694514,2042.0,2049.0,2038,2056,4.9941459711621725
NCT06592131,BF844 Safety and Pharmacokinetic Study in Healthy Volunteers,PHASE1,EyeXCel Pty. Ltd.,0.4823,2040.0,2040.411362222683,2037.0,2044.0,2034,2050,2045.0,2045.4391457599004,2042.0,2049.0,2038,2055,5.045296893223601
NCT05805007,Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa,EARLY_PHASE1,Peking University Third Hospital,0.438,2040.0,2040.466894977169,2037.0,2044.0,2034,2049,2045.0,2045.4746575342465,2042.0,2049.0,2038,2055,5.005384932373605
NCT04611503,PDE6A Gene Therapy for Retinitis Pigmentosa,"PHASE1, PHASE2",STZ eyetrial,0.4242,2040.0,2040.478783592645,2037.0,2044.0,2034,2049,2045.0,2045.468882602546,2042.0,2049.0,2037,2055,4.9860544383976455
NCT06936787,"An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa",PHASE1,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",0.4826,2040.0,2040.4208454206382,2037.0,2044.0,2034,2050,2045.0,2045.4481972648157,2042.0,2049.0,2037,2056,5.036741467498059
NCT05282953,"A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia (ABACUS)","PHASE1, PHASE2","Kiora Pharmaceuticals, Inc.",0.4895,2040.0,2040.4621041879468,2037.0,2044.0,2034,2050,2045.0,2045.473340143003,2042.0,2049.0,2038,2055,5.010775210443782
NCT04517149,4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP),"PHASE1, PHASE2",4D Molecular Therapeutics,0.4901,2040.0,2040.3778820648847,2037.0,2044.0,2033,2050,2045.0,2045.383799224648,2042.0,2049.0,2037,2055,4.997505750684868
NCT06591793,Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa,"PHASE1, PHASE2",AAVantgarde Bio Srl,0.4352,2040.0,2040.4673713235295,2037.0,2044.0,2034,2050,2045.0,2045.47265625,2042.0,2049.0,2037,2055,5.0062328864669166
NCT06789445,A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO),"PHASE1, PHASE2",BlueRock Therapeutics,0.48,2040.0,2040.4508333333333,2037.0,2044.0,2033,2050,2045.0,2045.4622916666667,2042.0,2049.0,2038,2056,5.004757312865722
NCT06565572,Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1,EARLY_PHASE1,"University of Colorado, Denver",0.4897,2040.0,2040.4092301409025,2037.0,2044.0,2034,2049,2045.0,2045.3922809883602,2042.0,2049.0,2038,2055,4.976146162919691
NCT04278131,BS01 in Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Bionic Sight LLC,0.4753,2040.0,2040.3797601514832,2037.0,2044.0,2033,2049,2045.0,2045.383757626762,2042.0,2049.0,2037,2055,5.022785074537385
NCT02018692,The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Sheba Medical Center,0.4798,2040.0,2040.4695706544394,2037.0,2044.0,2033,2049,2045.0,2045.4604001667362,2042.0,2049.0,2037,2055,4.981042984576305
NCT06460844,Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION),PHASE1,"Ray Therapeutics, Inc.",0.487,2040.0,2040.3870636550307,2037.0,2044.0,2034,2050,2045.0,2045.3862422997947,2042.0,2049.0,2038,2055,5.006362862050489
NCT01680510,The Effect of Oral Administration of 9-cis Î² Carotene Rich Powder of the Alga Dunaliella Bardawil,"PHASE1, PHASE2",Sheba Medical Center,0.4851,2040.0,2040.46423417852,2037.0,2044.0,2033,2051,2045.0,2045.4662956091527,2042.0,2049.0,2038,2056,4.997973584463802
NCT05147701,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION,PHASE1,The Foundation for Orthopaedics and Regenerative Medicine,0.4306,2040.0,2040.3722712494193,2037.0,2044.0,2034,2050,2045.0,2045.3706456107757,2042.0,2049.0,2038,2056,5.0042572024838226
NCT04355689,Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome,"PHASE1, PHASE2","Nacuity Pharmaceuticals, Inc.",0.4897,2040.0,2040.429242393302,2037.0,2044.0,2034,2050,2045.0,2045.433734939759,2042.0,2049.0,2037,2055,4.991494512521787
NCT06891885,A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older with Retinitis Pigmentosa,"PHASE1, PHASE2","Sumitomo Pharma America, Inc.",0.4797,2040.0,2040.4213049822806,2037.0,2044.0,2033,2050,2045.0,2045.3952470293934,2042.0,2049.0,2038,2057,4.9732058400817785
NCT03963154,Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation,"PHASE1, PHASE2",Centre d'Etude des Cellules Souches,0.4811,2040.0,2040.3974225732695,2037.0,2044.0,2034,2050,2045.0,2045.4017875701518,2042.0,2049.0,2037,2056,5.001689429213987
